Why the study?
East Asian patients experience reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients, making their unique risk-benefit trade-off an emerging clinical challenge.
This position statement highlights the 'East Asian Paradox' of increased bleeding and reduced anti-ischemic benefit with potent antithrombotics, calling for tailored strategies in this population.
Supports tailored antithrombotic strategies in East Asians; leaves open optimal regimens pending dedicated prospective trials.
East Asian patients have reduced anti-ischemic benefits and increased bleeding risk during antithrombotic therapies compared with Caucasian patients. As potent P2Y₁₂ receptor inhibitors (e.g., ticagrelor and prasugrel) and direct oral anticoagulants are commonly used in current daily practice, the unique risk-benefit trade-off in East Asians has been a topic of emerging interest. In this article, we propose updated evidence and future directions of antithrombotic treatment in East Asian patients.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: